Detecting counterfeit drug Molnupiravir in Switzerland, with information in Vietnamese

The Drug Administration of Vietnam (Ministry of Health) on May 5 sent an official dispatch to the Departments of Health of the provinces/cities warning about the counterfeit drug Molnupiravir detected in Switzerland on the label with Vietnamese information.

Previously, the Drug Administration of Vietnam received information from the Representative Office of the World Health Organization (WHO) in Vietnam to send an urgent warning from WHO Headquarters regarding the counterfeit drug Molnupiravir detected in Switzerland.

Accordingly, Swiss Customs has detected fake drug Molnupiravir 400mg, hard capsule dosage form, packing specification: vial of 20 hard capsules, on the label there is information stating “Manufactured by Co., Ltd., Quick cost 1 over 40” dai, An Phu Ward, Tx. Thuan An, Tinh Binh Duong, Vietnam”.

The drug test results showed that the drug did not contain the active ingredients as stated on the label.

In order to ensure the safety of users and strictly handle violations according to the provisions of the law, the Drug Administration of Vietnam proposes the Departments of Health of the provinces and centrally-run cities to notify business and user establishments. drug use and on the website of the Department of Health about counterfeit drugs Molnupiravir 400mg have the above signs.

Along with that, this Department also suggested the local health sector to coordinate with agencies to communicate information to business establishments, drug users and people to know so as not to trade and use fake drugs Molnupiravir 400mg that can contain fake drugs. the above signs.

The specialized agencies of the Ministry of Health request the Departments of Health of the provinces/cities to organize the receipt of information and reports from drug-using and trading establishments; coordinate with relevant functional agencies in inspecting, verifying, tracing the origin of the above-mentioned counterfeit drugs, and handle violating organizations and individuals according to current regulations.

Molnupiravir is an antiviral drug used to treat mild to moderate COVID-19 in adults who are positive for a diagnostic test for SARS-CoV-2 and have at least one risk factor for progression of the disease. heavy.

According to the recommendations of the specialized agency of the Ministry of Health, do not use Molnupiravir for more than 5 consecutive days. Do not use Molnupiravir for pre- or post-exposure prophylaxis…

This medicine is not recommended for use during pregnancy. Molnupiravir is also not authorized for use in patients under 18 years of age because of possible effects on bone and cartilage growth.

Thanh Hien